Abstract: An instrumented trail-making task (iTMT) platform includes a wearable sensor and interactive interface technology configured to identify cognitive-cognitive impairment in individuals such as older adults. The iTMT platform may be programmed with neuropsychological tests for assessing individuals. The iTMT may provide information on visual search, scanning, speed of processing, mental flexibility, and/or executive functions as well as physical biomarkers of motor performance including slowness, weakness, exclusion, and/or motor planning error. Results of tests administered by the iTMT system may be reported to a patient or caregiver and used in identifying cogni-tive-motor impairment among individuals suffering from cognitive impairment, dementia, and/or those with frailty status, and/or cognitive frailty, and/or high risk of falling, and/or high likelihood of decline in cognitive-motor over time.

Abstract: Methods for the treatment of condition associated with bromodomain and extraterminal domain (BET) protein activity are disclosed. The methods include administering a therapeutically effective amount of a piperazine BET protein inhibitor or a piperidine BET protein inhibitor to a subject in need thereof. Piperazine BET protein inhibitors, piperidine BET protein inhibitors, and pharmaceutical compositions comprising the BET proteins inhibitors are also described.

Abstract: A wheelchair can comprise: a frame comprising an upper portion and a lower portion that is coupled to the upper portion so that the upper portion is vertically adjustable with respect to the lower portion. A pair of drive wheels can be coupled to the frame. A plurality (e.g., a pair) of casters are coupled to the frame. Each caster can have a respective swivel axis. At least one caster of the plurality of casters can be configured to be locked to prevent swiveling about its respective swivel axis and unlocked to enable swiveling about its respective swivel axis.

Abstract: Described herein are new synthetic routes for production of Endochin-Like Quinolone (ELQ) compounds. Synthetic routes to 3-substituted 4(1H)-quinolones are presented that are amenable to industrial scale preparation. One herein presented approach is relatively short, does not require palladium, and involves no chromatographic separation. A second herein presented approach is similarly relatively short, does not require palladium, involves no chromatographic separation, and also avoids high vacuum distillation. Additionally, both approaches require no protecting group chemistry because the insoluble 4(1H)-quinolone is not formed until the final reaction step.

Abstract: Provided herein are compositions and methods of use thereof for the treatment of metabolic disease such as diabetes and obesity. One embodiment provides a method of treating a metabolic disease or syndrome in a subject in need thereof by administering to the subject a therapeutically effective amount of a growth hormone releasing hormone (GHRH) antagonist or a pharmaceutical composition comprising the GHRH antagonist to reduce triglyceride-rich-lipoproteins (TRL) in the subject to treat the metabolic condition or syndrome.

Abstract: The present disclosures provides methods for decreasing injuries associated with intraoperative hypotension by intravenously administering to a subject a therapeutically effective amount of a fat emulsion, following a period of intraoperative hypotension and after the subject's mean arterial blood pressure has recovered. The disclosure also provides methods for preventing injuries associated with intraoperative hypotension, particularly for surgical candidates that have an increased risk for intraoperative hypotension. Non-limiting examples of injuries contemplated herein include myocardial injury, myocardial infarction, and acute kidney injury.

Abstract: This invention relates to pyrazolylacylpyrazoline compounds or pharmaceutically acceptable salts thereof, and for the use of the compounds to treat neurological disorders.

Abstract: Described herein are compositions and methods for treating pulmonary fibrosis and cancer. The compositions include growth hormone releasing hormone peptides. The methods include reducing lung inflammation, lung scarring, reducing expression of T cell receptor complex genes as well as inhibiting tumor growth.

Abstract: A chimeric antigen receptor is disclosed that includes: (a) an scFv comprising a light chain variable domain (VL) and a heavy chain variable domain (VH), wherein the scFv specifically binds to CCR4; (b) a hinge and transmembrane domain from CD8; (c) an intracellular 4-1BB signaling domain; and (d) an intracellular CD3 zeta signaling domain, wherein (a)-(d) are in N to C terminal order. Uses of the chimeric antigen receptor, such as for treating a malignancy, are also disclosed.

Abstract: Disclosed herein are methods and compositions for generating pacemaker cells from non-pacemaker cardiomyocytes. For example, the method includes the step of culturing the non-pacemaker cardiomyocytes with silk fibroin so that the silk fibroin induces the transformation of at least a portion thereof into pacemaker cells.

Abstract: The present disclosure provides a novel IKK2 inhibitor that does not target the kinase domain of IKK2 molecule. The novel IKK2 inhibitor is a cell penetrating NEMOActPep comprising a small segment (residues 384-389) of human NEMO to mediate interaction with and promote activation loop phosphorylation of IKK2. The NEMOActPep is derived from the second interaction interface of NEMO:IKK2 that is dependent upon NEMO binding to linear polyubiquitin. Methods of use the novel IKK2 inhibitor, and composition thereof, for preventing and/or treating inflammation in various diseases involving IKK-NF-?B signaling pathways are also provided.

Abstract: The present invention is directed to an integrated conceptual strategy for a gene delivery system, using the combination of nanoparticles, CRISPR-Cas9, and the HITI strategy to deliver CRISPR-Cas9 and achieve effective genome editing; wherein the advanced nanoparticles to overcome the limited packaging size of AAV-based vehicles.

Abstract: An apparatus can be used for assisting a user in donning a shoe, the shoe having a heel collar and a tongue, wherein the tongue has an underside. The apparatus can comprise a body that is partially receivable into the shoe. The body can have a top portion that is configured to extend above the heel collar when the body is partially received into the shoe. An inner portion can extend downwardly from the top portion. First and second projections that extend forwardly from the body and can be configured to bias against the underside of the tongue on opposing sides of the tongue.

Abstract: Disclosed are small molecule PTPRD inhibitors and uses thereof. Methods of using the PTPRD inhibitors include methods of treating, preventing, or delaying the progression of a disorder responsive to PTPRD inhibition, including for example nicotine dependence, addiction, obesity, metabolic syndrome, and substance-use disorders such as stimulant-use disorders and opioid-use disorders.

Abstract: A method is to be implemented by a computing device that stores a risk assessment model, and includes steps of: obtaining an entry of target physiological data and target magnetic resonance imaging (MRI) images of a brain of a subject with mild cognition impairment (MCI); obtaining, based on the target MRI images, voxel values respectively of primitive voxels that are related to grey matter of the brain of the subject; selecting, from among the primitive voxels, any primitive voxel satisfying a filtering criterion as a selected voxel; calculating an average of the voxel value(s) respectively of the selected voxel(s) to obtain an average target voxel value; and obtaining a probability of the subject developing Alzheimer's disease within a predetermined time period by feeding the average target voxel value and the entry of target physiological data into the risk assessment model.

Abstract: Compounds which are benzoxazolone derivatives are disclosed, including compounds of the following genus: The compounds possess anti-inflammasome properties and exhibit anti-fibrotic and anti-proliferative effects. They are useful in inhibiting the activation of NLRP3 or NLRC4 receptors, and in the treatment of a variety of neuroinflammatory disorders such as autoimmune diseases, type-2 diabetes, Cryopyrin-Associated Autoinflammatory Syndromes, Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and rheumatoid arthritis.

Abstract: Provided herein are compositions suitable for treating chemically induced eye damage comprising (a) a nonsteroidal anti-inflammatory drug (NSAID), (b) a histone deacetylase (HDAC) inhibitor and (c) an angiotensin converting enzyme (ACE) inhibitor and, optionally, (d) a water-soluble vitamin. Methods of using provided compositions to treat ocular toxicity and corneal damage following exposure to chemical agents (e.g., mustard gas) are also provided.

Abstract: Disclosed herein are contractile cell constructs, methods for using them to treat disease, and methods for making them.

Abstract: A cleaning cart can comprise a body defining an underside and at least one shelf, wherein the body has a footprint. A plurality of wheels can rotatably couple to the body. A sweeping attachment can be coupled to the underside of the body. The sweeping attachment can comprise a slide comprising a track that is coupled to the body and a carriage that is configured to slide relative to the track along an axis about and between a first position that is generally within the footprint of the body and a second position that is generally outside of the footprint of the body. A sweeping assembly can be coupled to the carriage. The sweeping assembly can couple to a sweeping element.